Survey Methodology: The 2014 Eleventh Annual Report and Survey of
Biopharmaceutical Manufacturing Capacity and Production yields a composite view and trend
analysis from 238 responsible individuals at biopharmaceutical manufacturers and contract
manufacturing organizations (CMOs) in 31 countries. The methodology also included 158
direct suppliers of materials, services and equipment to this industry. This year's study covers such issues as: new product needs, facility budget changes, current capacity, future capacity constraints, expansions, use of disposables, trends and budgets in disposables, trends in
downstream purification, quality management and control, hiring issues, and employment.
The quantitative trend analysis provides details and comparisons of production by biotherapeutic developers and CMOs. It also evaluates trends over time, and assesses differences in
the world's major markets in the U.S. and Europe.
high profit margins, most are likely to focus on maximizing their
returns on their current product lines for several years to come.
In the meantime, that leaves little incentive for introducing new,
paradigm-shifting or revolutionary, product lines. As such, those
companies that do bring innovations to the market could become
acquisition targets as the current players eventually position
themselves with next-generation and more innovative lines.
11th Annual Report and Survey of Biopharmaceutical
Manufacturing Capacity and Production, April 2014, Rockville, MD
About the Author:
Eric S. Langer can be reached at elanger@bioplanassociates.
Vcaps® Plus hypromellose capsules for pharmaceutical products
Secondary gelling agents and ionic gel promoters – used by other
HPMC capsules – may slow down release of active ingredients.
Capsugel’s Vcaps® Plus HPMC capsules are made through a proprietary
manufacturing process that eliminates the need for gelling systems.
They disintegrate and release their contents independent of pH and ionic
strength of the test media. Download our free whitepaper to discover
how Vcaps® Plus capsules can optimize performance, improve product
stability, and reduce drug development times.
Achieving new standards in performance takes
years of innovative R&D. This is the result.